by Lew Rockwell, Lew Rockwell:
Looking back, it appears the first realization that cancer had been cured occurred in 2008 when the world learned via this author that white blood cells known as macrophages could be activated to effect a cure. What happened in the aftermath is the subject of this report.
Background: abject failure to cure cancer
False claims of cancer cures are not being made by health quacks but by degreed doctors and “ethical” medical institutions. Cancer care is a business and any dent in the volume of care (1.7 million diagnosed/year) would financially threaten a $175 billion industry. Modern medicine can’t afford to cure cancer says a striking report entitled The Cancer Industry: Hype vs. Reality (Scientific American).
TRUTH LIVES on at https://sgtreport.tv/
The cancer industry has reached a dead-end (no pun intended). The median cost for new cancer drugs is now above $150,000; the cost of a year of life gained $200,000; the estimated cost to eliminate cancer is $316,641 and would increase total healthcare expenditures 3-fold, thus bankrupting all healthcare programs. 1 in 3 cancer patients must turn to friends or family to pay for care. Possibly reallocation of funds toward cancer prevention would spare health plans from insolvency, but the problem is that many cancers are not detected until it is too late.
Of current interest, ~6% of Covid-19 patients have developed cancer, 1.8-fold greater than those without cancer. Immunotherapy would address both diseases.
Horrible track record for cancer care
- The lifetime risk for cancer is ~40% in humans but just 4% in most all other large-bodied species of animals.
- The 2-year survival of newly diagnosed cancer patients is just 7% over the past 27 years of the War On Cancer.
- Chemotherapy kills cancer patients before their disease does.
- 70% of tumors are solid masses that chemo and radiation cannot penetrate. The treatment failure rate for solid tumors is ~90%.
- Tumor-drug resistance sets in 100% of the time.
- Chemotherapy achieves in 5-year survival only 2% of the time.
- The mortality rate for all cancer in the US, ~152.4 deaths per 100,000 people, hasn’t budged since 1930. In recent decades, the cancer mortality rate has continued to rise.
- Most people who die of cancer exhibit symptomless spread (metastasis) throughout their body. Therefore, the only chance for a cure or prolonged survival is systemic therapy rather than targeted localized treatment.
The cause of cancer remains a confusion, with the statement cancer is 200 different diseases. Yes, but its cure lies within the body, not in some new monoclonal antibody or tricked-out treatment that costs hundreds of thousands of dollars.
In 1962 Dr. Chester Southam injected millions of cancer cells into elderly patients to prove the human immune system is capable of resisting cancer even when attempts are made to intentionally induce malignancy.
The re-introduction of macrophage therapy
The question of whether modern medicine will ever move away from its treatment-centered approach of disease care towards a curative paradigm is now being tested with the introduction of macrophage therapy. Macrophages (mack-row-fay-jes) are the paramount governors of the human immune system. Macrophages often remain dormant and sluggish as tumor cells and viruses dull the immune response. In the past researchers demonstrated how to activate macrophages, but modern medicine shunned that discovery. If unguided cancer patients want to pursue this macrophage “cure” they have to opt out of the disease-care system.
Once before modern medicine attempted to invigorate macrophages via a monoclonal antibody (a laboratory- produced molecule that substitutes for natural antibodies), but side effects, elevated costs and treatment resistance problems caused this widely heralded treatment to fizzle.
Dr. Yamamoto’s nagalase theory of cancer
From 1990 to 2011 a noted researcher, Nobuto Yamamoto, operating out of what he called The Socrates Institute in his home in Philadelphia, and who is now in his 90s, published ground-breaking human studies to demonstrate that nagalase, an enzyme secreted by viruses and tumor cells, degrades macrophage activating factor (MAF), essentially disarming the large army of reserve macrophages that would normally engulf and kill viruses and tumor cells.
Dr. Yamamoto published four papers that revealed MAF therapy cured colon, breast, prostate and lung cancer in humans with remissions lasting 4-7 years when subjects were administered just 100 billionths of a gram of MAF. Similar studies produced the same result. Yamamoto’s monumental achievement was ignored. This author along with laboratory scientist and tipster Timothy Hubbell broke this story in 2008 to the public at large.
Modern medicine wasn’t ready to accept Dr. Yamamoto’s definition of a cure, which was to administer macrophage activating factor (MAF), a derivative of vitamin D-binding (transport) protein, and measure its effectiveness by charting nagalase enzyme levels, thus effecting a cure. But alleged deficiencies in his research papers resulted in his work being discredited. Some of his published papers were retracted. Such is the fate of anyone who cures cancer. We have reached a point where any cure for cancer is a threat to a $175 billion industry.
Is modern medicine finally going to put macrophage therapy to the test?
Fast forward—a recently published report entitled “Targeting macrophages in cancer immunotherapy,” suggests modern medicine may turn its cannons around and begin learning how to use macrophage therapy for otherwise unconquerable maladies. But we’ve been down this road before.
That report concedes that there are limitations of traditional cancer treatments, the slash, burn and poison approach to cancer has failed, and immunotherapy has become the most promising cancer treatment.
Furthermore, it’s not like macrophage therapy has been completely abandoned. There are over 150 human clinical trials, some withdrawn, some terminated, that involved macrophage-targeting agents. A report says: “Macrophages provide a force to be considered in immunotherapy and might be a new door for oncotherapy.”